Gyre Therapeutics (GYRE) Long-Term Deferred Tax (2022 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Long-Term Deferred Tax of $7.7 million for Q1 2026, up 32.74% year-over-year from $5.8 million in Q1 2025, and up 12.37% quarter-over-quarter from $6.9 million in Q4 2025.
Gyre Therapeutics (GYRE) Long-Term Deferred Tax (2022 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Long-Term Deferred Tax for 5 consecutive years, with $7.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Deferred Tax rose 32.74% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $7.7 million (up 32.74% YoY), while the FY2025 annual figure was $6.9 million, up 22.32% from the prior year.
- Long-Term Deferred Tax rose to $7.7 million in Q1 2026 per GYRE's latest filing, from $6.9 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $7.7 million in Q1 2026 and bottomed at $4.1 million in Q4 2022.
- Historically, Long-Term Deferred Tax has averaged $5.7 million across 5 years, with a median of $5.6 million in 2024.
- Annual changes were most pronounced in 2023 — Long-Term Deferred Tax climbed 15.05% — and 2026, when it surged 32.74%.
- Gyre Therapeutics' Long-Term Deferred Tax stood at $4.1 million in 2022, then rose by 15.05% to $4.7 million in 2023, then climbed by 19.68% to $5.6 million in 2024, then climbed by 22.32% to $6.9 million in 2025, then rose by 12.37% to $7.7 million in 2026.
- Business Quant data shows GYRE's Long-Term Deferred Tax at $7.7 million in Q1 2026, $6.9 million in Q4 2025, and $6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.28 Mn |
| Mar 31, 2026 | 7.72 Mn |
| Dec 31, 2025 | 6.87 Mn |
| Sep 30, 2025 | 6.71 Mn |
| Jun 30, 2025 | 6.13 Mn |
| Mar 31, 2025 | 5.82 Mn |
| Dec 31, 2024 | 5.62 Mn |
| Sep 30, 2024 | 5.16 Mn |
| Jun 30, 2024 | 5.08 Mn |
| Mar 31, 2024 | 5.00 Mn |
| Dec 31, 2023 | 4.70 Mn |
| Dec 31, 2022 | 4.08 Mn |